What is Peptris?
Peptris operates at the intersection of artificial intelligence and biotechnology, focusing on the generation of novel molecules and the rescue of existing drug candidates. The company has distinguished itself by transitioning from a purely computational model to a tangible clinical development entity, underscored by the successful licensing of its inaugural program targeting Duchenne Muscular Dystrophy. Its market position is defined by a nimble, data-centric approach that addresses the inefficiencies of the drug discovery pipeline, positioning the firm as a critical player in the evolving landscape of AI-led life sciences. By integrating deep-tech capabilities with pharmaceutical rigor, Peptris is redefining the speed and precision of therapeutic innovation.
How much funding has Peptris raised?
Peptris has raised a total of $8.7M across 2 funding rounds:
Other Financing Round
$1M
Series A
$7.7M
Other Financing Round (2023): $1M with participation from Speciale Invest
Series A (2026): $7.7M led by Indian Angel Network, Tenacity Ventures, Speciale Invest, and BYT Capital
Key Investors in Peptris
Tenacity Ventures
An early-growth investment firm targeting Series A to C stages, focusing on gritty founders and breakthrough technologies with strong intellectual property potential.
BYT Capital
A venture firm dedicated to accelerating science-led companies from Pre-seed to Series A, providing strategic expertise across biotech and artificial intelligence sectors.
Speciale Invest
A venture capital firm specializing in early-stage investments for disruptive technologies, with a strong focus on human longevity and AI-led software solutions.
What's next for Peptris?
With this major enterprise-level funding, Peptris is poised to scale its operational capacity and expand its pipeline of therapeutic candidates. The strategic allocation of capital will likely prioritize the advancement of its clinical-stage programs and the further refinement of its AI-driven discovery engine. As the company moves deeper into the clinical development phase, the focus will shift toward validating its NCEs in human trials and securing additional licensing partnerships. The backing from specialized deep-tech investors suggests a long-term commitment to building a high-margin, intellectual property-heavy business capable of achieving significant scale in the global biopharmaceutical market.
See full Peptris company page
